Novo Nordisk’s (NVO) top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight loss drug Wegovy, leaving the drugmaker in a more vulnerable position when Eli Lilly (LLY) entered the market, Reuters’ Jacob Gronholt-Pedersen and Maggie Fick report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk (NVO) Partners with WeightWatchers After Hims & Hers Fallout
- Novo Nordisk Stock (NVO) Inches Higher Despite More U.K. Weight Jab Concerns
- Novo Nordisk announces WeightWatchers collaboration for Wegovy
- Is the Hims & Hers Stock (HIMS) Crash a Hidden Buying Opportunity?
- Citi sees tiered orforglipron pricing $15B opportunity for Eli Lilly